{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018835","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.899694+00:00","generated_at":"2026-06-08T05:14:15.933761+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeuroBo Q3 2023 net loss $3.8M; cash $25.8M; DA-1241 Phase 2a first patient dosed","bullets":["Net loss $3.8M in Q3 2023 (EPS -$0.09) compared to net loss $3.1M (EPS -$3.50) in Q3 2022.","Cash and cash equivalents $25.8M as of Sep 30, 2023; expected to fund operations into Q4 2024.","First patient dosed in Phase 2a trial of DA-1241 for NASH; interim data expected H1 2024, full data H2 2024.","DA-1726 IND submission for obesity expected by year-end 2023; Phase 1a initiation targeted H1 2024.","Appointed James P. Tursi, M.D. to Board of Directors in November 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018835","json":"https://secwatch.observer/filing/0001558370-23-018835.json","markdown":"https://secwatch.observer/filing/0001558370-23-018835.md","text":"https://secwatch.observer/filing/0001558370-23-018835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023018835/0001558370-23-018835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023018835/nrbo-20231113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:14:15.933761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62581499d900fedef6959c1eb0d089909eba30f8","claim":"MetaVia Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, NeuroBo Pharmaceuticals, Inc. (the “Company” ) issued a press release announcing its financial results for the third quarter ended September 30, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023018835/0001558370-23-018835-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}